Search
Non-Small Cell Lung Cancer Paid Clinical Trials in Minnesota
A listing of 23 Non-Small Cell Lung Cancer clinical trials in Minnesota actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 23
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Non-Small Cell Lung Cancer
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Herpes Clinical Trial
Recruiting
Help move the future of herpes simplex virus type 2 (HSV-2) genital herpes forward by participating in the Vantage Trial for an investigational vaccine.
Conditions:
HSV-2 Infection
HSV-2
Herpes
Herpes Simplex
Genital Herpes
Genital Herpes Simplex Type 2
HSV-2 Genital Herpes
HIV-1 and HSV-2 Coinfection
Featured Trial
Fronto-Temporal Dementia Research Study
Recruiting
The aim of this study is to better understand the genetics of FTD, in order to
empower researchers with the data they need to potentially identify treatment
options. Help researchers accelerate their understanding of Frontotemporal
Dementia and get access to free, at-home genetic testing and genetic counseling
before and after your test.
empower researchers with the data they need to potentially identify treatment
options. Help researchers accelerate their understanding of Frontotemporal
Dementia and get access to free, at-home genetic testing and genetic counseling
before and after your test.
Conditions:
Dementia
Frontotemporal Dementia
Alzheimer Dementia
Dementia Alzheimers
Mild Dementia
Dementia
Alzheimer Type
Alzheimer Disease
Alzheimer's Disease
Dementia of Alzheimer Type
Parkinson's Disease
Parkinson Disease
Idiopathic Parkinson's Disease
ALS
Memory Disorders
Memory Impairment
Memory Loss
Age-Related Memory Disorders
Featured Trial
Clinical Research for Alpha-1 Antitrypsin Deficiency–Associated Liver Disease
Recruiting
The Redwood Study is currently enrolling adults 18 to 75 years of age with Alpha-1
Liver Disease. The purpose of the study is to evaluate how safe and effective an
investigational study drug is compared to a placebo (both groups will receive
injections, but the placebo contains no active medication) in the treatment of liver
disease. If you or any of your family members have a confirmed or suspected
diagnosis of Alpha-1 Liver Disease, you may be eligible.
Liver Disease. The purpose of the study is to evaluate how safe and effective an
investigational study drug is compared to a placebo (both groups will receive
injections, but the placebo contains no active medication) in the treatment of liver
disease. If you or any of your family members have a confirmed or suspected
diagnosis of Alpha-1 Liver Disease, you may be eligible.
Conditions:
Crohn's Disease
COPD
Chronic Obstructive Pulmonary Disease (COPD)
Emphysema or COPD
Alpha 1-Antitrypsin Deficiency
AAT Deficiency
AATD
Chronic Obstructive Pulmonary Disease
Emphysema
Pulmonary Emphysema
Bronchiectasis
Panniculitis
Hepatocellular Carcinoma
Cirrhosis
Liver Cirrhosis
Cirrhosis
Liver
Cystic Fibrosis
Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
Non-Alcoholic Fatty Liver Disease
Liver Diseases
Liver Disease
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)
Recruiting
Tomivosertib combined with pembrolizumab in Subjects with PD-L1 positive NSCLC
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Metro Minnesota CCOP, Saint Louis Park, Minnesota
Conditions: Non-small Cell Lung Cancer
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Recruiting
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab or AZD0171 and platinum doublet chemotherapy; or MEDI5752 in combination with platinum doublet chemotherapy or datopotamab deruxtecan (Dato-DXd) in combination with durvalumab and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
Gender:
All
Ages:
Between 18 years and 95 years
Trial Updated:
11/30/2023
Locations: Research Site, Saint Louis Park, Minnesota
Conditions: Non-small Cell Lung Cancer
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
Recruiting
The purpose of this study is to evaluate BMS-986442 in combination with nivolumab (with or without chemotherapy) for its antitumor efficacy and benefit to participants.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota
Conditions: Advanced Solid Tumors, Non-small Cell Lung Cancer
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Recruiting
This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic).
The study will also find out what side effects occur. A side effect is anything the treatment does besides treat cancer.
This is a multi-cohort study.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Minnesota Oncology Hematology P.A., Minneapolis, Minnesota
Conditions: Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
Recruiting
The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with unresected stage I or II (Stage IIB N0, M0) non-small cell lung cancer (NSCLC).
The primary study hypotheses are:
SBRT plus pembrolizumab prolongs Event-free Survival (EFS) compared to SBRT plus placebo (normal saline solution), and
SBRT plus pembrolizumab prolongs Overall Survival (OS) compared to SBRT plus placebo.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/23/2023
Locations: Sanford Bemidji ( Site 0080), Bemidji, Minnesota +1 locations
Conditions: Non-Small Cell Lung Cancer
A Study to Investigate LYL797 in Adults With Solid Tumors
Recruiting
This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC). The first part of the study will determine the safe dose for the next part of the study, and will enroll TNBC and NSCLC patients. The second part of the study will test that dose in additional TNBC and NSCLC patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/17/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
Recruiting
The purpose of the trial is to evaluate the safety of acasunlimab (also known as GEN1046) as monotherapy and in combination therapies in patients with malignant solid tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
11/16/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Solid Tumors, Non-small Cell Lung Cancer, Urothelial Carcinoma, Endometrial Carcinoma, Triple Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Cervical Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
Recruiting
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).
Gender:
All
Ages:
18 years and above
Trial Updated:
11/14/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC, PDAC, CRC, Relapsed Cancer, Refractory Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage III NSCLC, Stage IV NSCLC, KRAS Mutation-Related Tumors
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Recruiting
Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor (LXR), as a single agent and in combination with nivolumab, ipilimumab, docetaxel, or pembrolizumab plus carboplatin/pemetrexed.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/10/2023
Locations: Regions Hospital, Saint Paul, Minnesota
Conditions: Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Recruiting
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/03/2023
Locations: Research Site, Duluth, Minnesota +1 locations
Conditions: Non-Small Cell Lung Cancer
Phase 3 Clinical Study of AK112 for NSCLC Patients
Recruiting
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of Ivonescimab (SMT112 or AK112) or Placebo Plus Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi)
Gender:
All
Ages:
18 years and above
Trial Updated:
11/02/2023
Locations: HealthPartners Cancer Research Center, Saint Paul, Minnesota
Conditions: Non-Squamous Non-small Cell Lung Cancer
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
Recruiting
The purpose of the study is to compare progression-free survival (PFS) between Arm A (ociperlimab in combination with tislelizumab) and Arm B (pembrolizumab in combination with placebo) as assessed by investigators according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) and to compare overall survival (OS) between Arm A and Arm B.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/02/2023
Locations: Metro Minnesota Community Oncology Research Consortium (Mmcorc), Saint Paul, Minnesota
Conditions: Non-small Cell Lung Cancer, NSCLC
1 - 12 of 23